Wednesday, May 17, 2017

Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug

Source: The Life Sciences Report   05/17/2017

In light of a decision to pull its application for approval of vosaroxin in the European Union, Sunesis Pharmaceuticals has designated its BTK inhibitor program targeting chronic lymphocytic leukemia as its new lead program.

In a May 1 research report, Wells Fargo expressed the view that SNS062, the Sunesis Pharmaceuticals Inc. (SNSS:NASDAQ) drug in development for patients with chronic lymphocytic leukemia (CLL) that is resistant to Imbruvica (ibrutinib), is "a greater value driver for the stock."

The report notes that company resources directed toward gaining approval from the European Medicines Agency for vosaroxin, which targets acute myeloid leukemia, will now be directed toward a clinical trial for SNS062.

"We see significant upside potential on novel BTK inhibitor SNS062 in the large IMBRUVICA resistance market and with potential validation by YE17," the Wells Fargo report concludes.

In a May 10 report, Edison Investment Research states that Sunesis "will be initiating a Phase Ib/II clinical trial in Q217" for SNS062. The study is expected to read out in September 2018.

Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

Disclosure:
1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own shares of the following companies mentioned in this article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned are sponsors of Streetwise Reports: Sunesis Pharmaceuticals Inc. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

Additional disclosures about the sources cited in this article

( Companies Mentioned: SNSS:NASDAQ, )



from Streetwise Reports - Exclusive Articles https://www.streetwisereports.com/pub/na/17444

No comments:

Post a Comment